Trial Profile
A first-in-human study of INS-3001 in Vascular calcification
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Feb 2022
Price :
$35
*
At a glance
- Drugs INS 3001 (Primary)
- Indications Vascular calcification
- Focus Adverse reactions; First in man
- 17 Feb 2022 Status changed from planning to recruiting, according to a Vifor Pharma media release.
- 17 Feb 2022 According to a Vifor Pharma media release, announced the acquisition of Inositec AG in November, receiving full global rights for the lead asset INS-3001, in development for treatment of the vascular calcification disorders Peripheral Artery Disease and Aortic Valve Stenosis in non-dialysis patients
- 17 Feb 2022 According to a Vifor Pharma media release, a phase-I study of INS-3001 started in 2021.